ARTICLE | Clinical News
MVA-HPV-IL2: Started Phase II trial
December 24, 2001 8:00 AM UTC
Transgene S.A. (NM:Transgene; TRGNY), Strasbourg, France Product: MVA-HPV-IL2 Business: Gene/Cell therapy Therapeutic category: Gene therapy Target: Immune system Description: Vaccinia virus vector c...